Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies .......................... 1223
K.P. Liao, V. Bykerk

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis J.E. Homik ................................. 1225

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano,
S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri ............................... 1228

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau ................................................................. 1231

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists

E.C. Keystone, K.A. Papp, W. Wobeser ........................................... 1234

Articles

Lymphotoxin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?


Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort

S. Varache, D. Cornec, J. Morvan, et al ........................................... 1250

Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety

Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group ................................................................. 1258

A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis

A. Svard, A. Kastborn, M.K. Söderlin, A. Reckner-Olsson, T. Skogh ................................................................. 1265

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry


Time to Treatment for New Patients with RA in a Major Metropolitan City

S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier ................................................................. 1282

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China

X. Feng, Y. Zou, W. Pan, et al ................................................................. 1289

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression

A. Mak, Y. Liu, R.C-M Ho ................................................................. 1296

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis

K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos ................................................................. 1304

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms

A.D. Askanase, I. Castrejón, T. Pincus ................................................................. 1309

Late-age Onset SSc

R.L. Mannon, F.M. Wignley, A.C. Gelber, L.K. Hummers ........ 1317

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc

K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group ................................................................. 1326

Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies


Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial

S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi ................................................................. 1335

The SPARCC Registry for SpA


Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation

S.J. Pedersen, P. Chowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych ................................................................. 1349

Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARE Trial


High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA


Prevalence of Thyroid Autoimmunity in Patients with SpA


Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene

S. Borghini, M. Fiore, M. Di Duca, et al ........................................... 1378

Free online via JRheum Full Release option
Feduxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Undersecretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana ................................. 1385

Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study

Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
A.A. Khan, L.P. Rios, G.K.B. Sandor, et al .......................... 1396

Longterm Therapeutic Response to Minocycline Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group .......................... 1403

Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Design Analysis and RCT

Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace .......................... 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang .......................... 1429

Safety and Efficacy of Rituximab in Severe Juvenile DM:
Results from 9 Patients from the French Autoimmunity and Rituximab Registry
B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al for the Club Rhumatismes et Inflammation .......................... 1436

Development of IBD in Patients with JIA Treated with Etanercept

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis
S.G. Werner, H-E. Langer, G. Horneff ................................................. 1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010 Introduction .......................................................... 1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al .......................... 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?

Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials

Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
P.A. Merkel, S.Z. Aydin, M. Boers, et al .......................... 1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update
P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group .......................... 1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG
L.C. Coates, A. Muntaz, P.S. Helliswell, et al .......................... 1496

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde .......................... 1502


Developing Disease Activity and Response Criteria in CTD-related ILD
L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group .......................... 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger .......................... 1519

Reply R. Aiten ................................................. 1519

Lupus Related Longitudinal Myelitis
D.M. Wingerchuk, B.G. Weismenker ................................................. 1520

Reply P. Zotos ................................................. 1521


Who Discovered the ESR? A. Grzybowski, J.J. Sak .......................... 1521

Reply E.L. Matteson, C.S. Crowson ................................................. 1523

Letters

Serum Levels of HMGB1 in Postmenopausal Patients with RA: Associations with Prolinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics
R. Pullerits, V. Urbanoviciute, R.E. Voll, H. Forssblad-D’Elia, H. Carlsten ................................................. 1523

Acute Presentation of Tophaceous Myelopathy
E. Levin, K. Kurth, R. Joshi, R. Brasington .......................... 1525

AS Refractory to TNF Blockade Responds to Tocilizumab
J-D. Cohen, R. Ferreira, C. Jorgensen .......................... 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis
M. Uh, I.A. McCormick, J.T. Kelsall .......................... 1528

Primary Aldosteronism Simulating Polymyositis

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial
J.A. Singh, M.L. Mahowald, S. Noorbalkouchi .......................... 1534


Meetings in Rheumatology